Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Evaluation of Dose Fractionated Polymyxin B on Acute Kidney Injury: A Translational In Vivo Rat Model.

Liu J, Pais GM, Avedissian SN, Gilchrist A, Lee A, Rhodes NJ, Hauser AR, Scheetz MH.

Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02300-19. doi: 10.1128/AAC.02300-19. [Epub ahead of print]

PMID:
32071049
2.

Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.

Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d'Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH.

J Antimicrob Chemother. 2020 Feb 3. pii: dkz563. doi: 10.1093/jac/dkz563. [Epub ahead of print]

PMID:
32011685
3.

Piperacillin-Tazobactam Added to Vancomycin Increases Risk for AKI: Fact or Fiction?

Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH.

Clin Infect Dis. 2019 Dec 13. pii: ciz1189. doi: 10.1093/cid/ciz1189. [Epub ahead of print]

PMID:
31833540
4.

β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.

Wong G, Taccone F, Villois P, Scheetz MH, Rhodes NJ, Briscoe S, McWhinney B, Nunez-Nunez M, Ungerer J, Lipman J, Roberts JA.

J Antimicrob Chemother. 2020 Feb 1;75(2):429-433. doi: 10.1093/jac/dkz437.

PMID:
31665353
5.

Mechanisms of antimicrobial-induced nephrotoxicity in children.

Downes KJ, Hayes M, Fitzgerald JC, Pais GM, Liu J, Zane NR, Goldstein SL, Scheetz MH, Zuppa AF.

J Antimicrob Chemother. 2020 Jan 1;75(1):1-13. doi: 10.1093/jac/dkz325.

PMID:
31369087
6.

Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model.

Joshi MD, Pais GM, Chang J, Hlukhenka K, Avedissian SN, Gulati A, Prozialeck WC, Lamar PC, Zhang Z, Scheetz MH, Griffin B.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00761-19. doi: 10.1128/AAC.00761-19. Print 2019 Oct.

PMID:
31332061
7.

Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model.

Avedissian SN, Pais GM, O'Donnell JN, Lodise TP, Liu J, Prozialeck WC, Joshi MD, Lamar PC, Becher L, Gulati A, Hope W, Scheetz MH.

J Antimicrob Chemother. 2019 Aug 1;74(8):2326-2334. doi: 10.1093/jac/dkz167.

PMID:
31065686
8.

Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network.

Rhodes NJ, Wagner JL, Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00327-19. doi: 10.1128/AAC.00327-19. Print 2019 Jul.

9.

Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury.

Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00079-19. doi: 10.1128/AAC.00079-19. Print 2019 Jul.

10.

A Review of the Clinical Pharmacokinetics of Polymyxin B.

Avedissian SN, Liu J, Rhodes NJ, Lee A, Pais GM, Hauser AR, Scheetz MH.

Antibiotics (Basel). 2019 Mar 22;8(1). pii: E31. doi: 10.3390/antibiotics8010031. Review.

11.

Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest.

Fitzgerald JC, Zane NR, Himebauch AS, Reedy MD, Downes KJ, Topjian AA, Furth SL, Thomas NJ, Scheetz MH, Zuppa AF.

Paediatr Drugs. 2019 Apr;21(2):107-112. doi: 10.1007/s40272-019-00328-8.

PMID:
30864056
12.

Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.

Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH.

Clin Infect Dis. 2019 Nov 13;69(11):1881-1887. doi: 10.1093/cid/ciz051.

13.

A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime.

Avedissian SN, Pais G, Joshi MD, Rhodes NJ, Scheetz MH.

mSphere. 2019 Jan 30;4(1). pii: e00595-18. doi: 10.1128/mSphere.00595-18.

14.

Understanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR).

Avedissian SN, Rhodes NJ, Liu J, Aljefri D, Postelnick MJ, Sutton SH, Zembower TR, Martin D, Pais G, Cruce CE, Scheetz MH.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01780-18. doi: 10.1128/AAC.01780-18. Print 2019 Mar.

15.

It is time to define antimicrobial never events.

Liu J, Kaye KS, Mercuro NJ, Davis SL, Patel TS, Petty LA, Pais GM, Scheetz MH.

Infect Control Hosp Epidemiol. 2019 Feb;40(2):206-207. doi: 10.1017/ice.2018.313. Epub 2018 Dec 5.

PMID:
30516126
16.

Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis.

Lee BJ, Wang SK, Constantino-Corpuz JK, Apolinario K, Nadler B, McDanel JS, Scheetz MH, Rhodes NJ.

Int J Antimicrob Agents. 2019 Mar;53(3):225-233. doi: 10.1016/j.ijantimicag.2018.11.013. Epub 2018 Nov 23.

PMID:
30476572
17.

Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent.

Miglis C, Rhodes NJ, Liu J, Gener J, Hang E, Scheetz MH.

Int J Antimicrob Agents. 2019 Jan;53(1):95-97. doi: 10.1016/j.ijantimicag.2018.10.004. Epub 2018 Oct 10.

PMID:
30315921
18.

Measuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmes.

Avedissian SN, Scheetz MH, Zembower TR, Silkaitis C, Maxwell R, Jenkins C, Postelnick MJ, Sutton SH, Rhodes NJ.

J Antimicrob Chemother. 2018 Oct 1;73(10):2876-2882. doi: 10.1093/jac/dky275.

PMID:
30085084
19.

Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago.

Wang SK, Gilchrist A, Loukitcheva A, Plotkin BJ, Sigar IM, Gross AE, O'Donnell JN, Pettit N, Buros A, O'Driscoll T, Rhodes NJ, Bethel C, Segreti J, Charnot-Katsikas A, Singh K, Scheetz MH.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00382-18. doi: 10.1128/AAC.00382-18. Print 2018 Aug.

20.

Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.

Avedissian S, Miglis C, Kubin CJ, Rhodes NJ, Yin MT, Cremers S, Prickett M, Scheetz MH.

Pharmacotherapy. 2018 May 25. doi: 10.1002/phar.2129. [Epub ahead of print]

PMID:
29800496
21.

Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.

O'Donnell JN, Rhodes NJ, Lopez J, Jett R, Scheetz MH.

Int J Antimicrob Agents. 2018 Oct;52(4):451-458. doi: 10.1016/j.ijantimicag.2018.04.011. Epub 2018 Apr 14. Review.

PMID:
29665442
22.

Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections.

McLaughlin MM, Miglis C, Skoglund E, Wagner J, Advincula MR, Scheetz MH.

J Glob Antimicrob Resist. 2018 Jun;13:261-263. doi: 10.1016/j.jgar.2018.02.003. Epub 2018 Feb 9.

PMID:
29432939
23.

Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP, Scheetz MH.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01475-17. doi: 10.1128/AAC.01475-17. Print 2018 Mar.

24.

Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.

Kubin CJ, Nelson BC, Miglis C, Scheetz MH, Rhodes NJ, Avedissian SN, Cremers S, Yin MT.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01493-17. doi: 10.1128/AAC.01493-17. Print 2018 Mar.

25.

Engaging Pharmacy Students in Research Through Near-Peer Training.

Lee BJ, Rhodes NJ, Scheetz MH, McLaughlin MM.

Am J Pharm Educ. 2017 Nov;81(9):6340. doi: 10.5688/ajpe6340.

26.

Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection.

Crew PE, Rhodes NJ, O'Donnell JN, Miglis C, Gilbert EM, Zembower TR, Qi C, Silkaitis C, Sutton SH, Scheetz MH.

Am J Infect Control. 2018 Mar;46(3):270-275. doi: 10.1016/j.ajic.2017.09.015. Epub 2017 Nov 21.

PMID:
29169938
27.

24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.

O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Miglis CM, Joshi MD, Venkatesan N, Pais G, Cluff C, Lamar PC, Briyal S, Day JZ, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov.

28.

Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies.

O'Donnell JN, Rhodes NJ, Miglis CM, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi MD, Griffin B, Prozialeck W, Gulati A, Lodise TP, Scheetz MH.

Int J Antimicrob Agents. 2018 Feb;51(2):239-243. doi: 10.1016/j.ijantimicag.2017.08.012. Epub 2017 Aug 10. Review.

29.

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP.

BMC Infect Dis. 2017 Aug 2;17(1):534. doi: 10.1186/s12879-017-2609-0.

30.

High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin.

Joshi MD, O'Donnell JN, Venkatesan N, Chang J, Nguyen H, Rhodes NJ, Pais G, Chapman RL, Griffin B, Scheetz MH.

Clin Transl Sci. 2017 Nov;10(6):496-502. doi: 10.1111/cts.12484. Epub 2017 Jul 4.

31.

Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumption.

Gilbert EM, Zembower TR, Rhodes NJ, Qi C, Reiner S, Malczynski M, Scheetz MH.

Diagn Microbiol Infect Dis. 2017 Sep;89(1):72-77. doi: 10.1016/j.diagmicrobio.2017.05.014. Epub 2017 Jun 2.

PMID:
28669681
32.

Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.

Rhodes NJ, Grove ME, Kiel PJ, O'Donnell JN, Whited LK, Rose DT, Jones DR, Scheetz MH.

Int J Antimicrob Agents. 2017 Sep;50(3):482-486. doi: 10.1016/j.ijantimicag.2017.04.008. Epub 2017 Jun 28.

PMID:
28668694
33.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

Miglis C, Rhodes NJ, Kuti JL, Nicolau DP, Van Wart SA, Scheetz MH.

Int J Antimicrob Agents. 2017 Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.

PMID:
28668683
34.

Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.

Zembower TR, Maxwell KM, Nadler RB, Cashy J, Scheetz MH, Qi C, Schaeffer AJ.

BMC Infect Dis. 2017 Jun 7;17(1):401. doi: 10.1186/s12879-017-2470-1.

35.

A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization.

Miglis C, Rhodes NJ, Avedissian SN, Zembower TR, Postelnick M, Wunderink RG, Sutton SH, Scheetz MH.

Infect Control Hosp Epidemiol. 2017 Jul;38(7):860-862. doi: 10.1017/ice.2017.72. Epub 2017 May 3.

PMID:
28464971
36.

Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Lodise TP.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):259-263. doi: 10.1016/j.diagmicrobio.2017.03.008. Epub 2017 Apr 2.

37.

Critical Need for Clarity in Polymyxin B Dosing.

Onufrak NJ, Rao GG, Forrest A, Pogue JM, Scheetz MH, Nation RL, Li J, Kaye KS.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00208-17. doi: 10.1128/AAC.00208-17. Print 2017 May. No abstract available.

38.

Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature.

Watson WA, Rhodes NJ, Echenique IA, Angarone MP, Scheetz MH.

J Clin Pharm Ther. 2017 Jun;42(3):350-355. doi: 10.1111/jcpt.12520. Epub 2017 Mar 29. Review.

39.

Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00185-17. doi: 10.1128/AAC.00185-17. Print 2017 Apr. No abstract available.

40.

Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.

Lee BJ, Rao SN, Wang SK, Lee JY, Lakada IY, Gilbert EM, Barr VO, Postelnick MJ, Sutton SH, Zembower TR, Bolon M, Scheetz MH, Rhodes NJ.

Int J Antimicrob Agents. 2017 May;49(5):650-654. doi: 10.1016/j.ijantimicag.2016.12.021. Epub 2017 Mar 6.

PMID:
28279787
41.

Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing.

O'Donnell JN, Ghossein C, Rhodes NJ, Peng J, Lertharakul T, Pham CK, Scheetz MH.

J Infect Chemother. 2017 May;23(5):326-332. doi: 10.1016/j.jiac.2016.12.011. Epub 2017 Jan 18.

42.

Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections.

Lizza BD, Rhodes NJ, Esterly JS, Toy C, Lopez J, Scheetz MH.

J Infect Chemother. 2016 Oct;22(10):671-6. doi: 10.1016/j.jiac.2016.07.006. Epub 2016 Aug 31.

PMID:
27590417
43.

Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.

Whited L, Grove M, Rose D, Rhodes NJ, Scheetz MH, O'Donnell JN, Neeb J, Thoele K, Jones DR, Lowe C, Moore D, Kiel PJ.

Pharmacotherapy. 2016 Sep;36(9):1003-10. doi: 10.1002/phar.1807. Epub 2016 Sep 6.

PMID:
27496678
44.

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51. doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

45.

Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics.

Rhodes NJ, Wagner JL, Gilbert EM, Crew PE, Davis SL, Scheetz MH.

Infect Control Hosp Epidemiol. 2016 Aug;37(8):971-3. doi: 10.1017/ice.2016.109. Epub 2016 May 13.

PMID:
27174570
46.

Pharmacokinetics of centhaquin citrate in a dog model.

O'Donnell JN, O'Donnell EP, Kumar EJ, Lavhale MS, Andurkar SV, Gulati A, Scheetz MH.

J Pharm Pharmacol. 2016 Jun;68(6):803-9. doi: 10.1111/jphp.12554. Epub 2016 Apr 25.

PMID:
27109141
47.

Investigating the Extremes of Antibiotic Use with an Epidemiologic Framework.

Scheetz MH, Crew PE, Miglis C, Gilbert EM, Sutton SH, O'Donnell JN, Postelnick M, Zembower T, Rhodes NJ.

Antimicrob Agents Chemother. 2016 May 23;60(6):3265-9. doi: 10.1128/AAC.00572-16. Print 2016 Jun.

48.

Genome Sequences of Five Clinical Isolates of Klebsiella pneumoniae.

Lopez LL, Rusconi B, Gildersleeve H, Qi C, McLaughlin M, Scheetz MH, Seshu J, Eppinger M.

Genome Announc. 2016 Mar 10;4(2). pii: e00040-16. doi: 10.1128/genomeA.00040-16.

49.

Carbapenem susceptibility breakpoints, clinical implications with the moving target.

O'Donnell JN, Miglis CM, Lee JY, Tuvell M, Lertharakul T, Scheetz MH.

Expert Rev Anti Infect Ther. 2016;14(4):389-401. doi: 10.1586/14787210.2016.1159131. Review.

PMID:
26918486
50.

Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.

O'Donnell JN, Venkatesan N, Manek M, Rhodes NJ, Scheetz MH.

Am J Health Syst Pharm. 2016 Feb 15;73(4):241-6. doi: 10.2146/ajhp150170.

PMID:
26843502

Supplemental Content

Loading ...
Support Center